ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Short Interest Update

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) saw a large decline in short interest in January. As of January 30th, there was short interest totaling 19,893 shares, a decline of 55.0% from the January 15th total of 44,222 shares. Approximately 0.7% of the company’s shares are short sold. Based on an average trading volume of 39,050 shares, the days-to-cover ratio is presently 0.5 days. Based on an average trading volume of 39,050 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.7% of the company’s shares are short sold.

ALPS Medical Breakthroughs ETF Price Performance

Shares of SBIO stock traded down $0.57 on Friday, reaching $49.72. 13,941 shares of the company were exchanged, compared to its average volume of 49,878. The company has a 50-day moving average of $51.30 and a 200-day moving average of $44.02. ALPS Medical Breakthroughs ETF has a one year low of $22.33 and a one year high of $54.79.

Institutional Trading of ALPS Medical Breakthroughs ETF

Hedge funds have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC bought a new position in shares of ALPS Medical Breakthroughs ETF in the fourth quarter valued at approximately $26,000. Comerica Bank purchased a new stake in shares of ALPS Medical Breakthroughs ETF in the third quarter valued at about $27,000. Global Retirement Partners LLC bought a new position in shares of ALPS Medical Breakthroughs ETF during the fourth quarter valued at about $34,000. Raymond James Financial Inc. bought a new position in shares of ALPS Medical Breakthroughs ETF during the second quarter valued at about $82,000. Finally, Ally Invest Advisors Inc. purchased a new position in ALPS Medical Breakthroughs ETF during the second quarter worth about $200,000.

About ALPS Medical Breakthroughs ETF

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.